Literature DB >> 14968919

Expression of transforming growth factor-beta and platelet-derived growth factor in linear scleroderma.

José Félix Restrepo1, Renato Guzmán, Gerzaín Rodríguez, Antonio Iglesias.   

Abstract

Linear scleroderma (LS) is a localized form of scleroderma characterized by mononuclear cell infiltration and fibroblast proliferation. In the later stages of the disease, excessive collagen is deposited with concomitant skin and appendage atrophy. These symptoms suggest a breakdown of fibroblast cell function, and consequently, growth factors have been thought to play a role in the pathogenesis of LS. The present study examined the expression of TGF-beta and PDGF in skin biopsies obtained from patients with LS and from normal subjects. Samples were prepared for immunohistochemistry. To identify TGF-beta, two polyclonal antibodies were used: TGF-beta1 (RaB4) and TGF-beta2 (CL-B1/29) and, to identify PDGF, two monoclonal antibodies were used: PDGF-AA (3E-205) and PDGF-BB (1F-133). Staining for TGF-beta1 and TGF-beta2 was observed around blood vessels (endothelial cells), and sweat glands in both LS and normal skin. Staining for PDGF-AA and PDGF-BB was intense in endothelial cells and sweat glands in LS and normal skin. Mononuclear cell infiltrates and abnormal collagen bundles did not stain for TGF-beta or PDGF. The strength and extent of staining was evaluated in tissues using a scale from zero (no staining) to four (strong staining). The amount of TGF-beta1, TGF-beta2, PDGF-AA and PDGF-BB was found similar in LS and normal skin. These results do not support the hypothesis that the excessive fibroblast cell activity and abnormal collagen deposition observed in LS are associated with downregulation of TGF-beta or PDGF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14968919

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  7 in total

1.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

2.  Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.

Authors:  Monica Brown; Arnold E Postlethwaite; Linda K Myers; Karen A Hasty
Journal:  Clin Rheumatol       Date:  2012-02-25       Impact factor: 2.980

3.  Transforming growth factor-β1 in plaque morphea.

Authors:  Aleksandra Dańczak-Pazdrowska; Michał J Kowalczyk; Beata Szramka-Pawlak; Justyna Gornowicz-Porowska; Aleksandra Szewczyk; Wojciech Silny; Marta Molińska-Glura; Anna Olewicz-Gawlik; Ryszard Zaba; Jakub Pazdrowski; Paweł Hrycaj
Journal:  Postepy Dermatol Alergol       Date:  2013-12-18       Impact factor: 1.837

4.  Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma.

Authors:  Jolanta Budzyńska-Włodarczyk; Małgorzata M Michalska-Jakubus; Małgorzata Kowal; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2016-02-29       Impact factor: 1.837

5.  Increased serum levels of TGFbeta1 in children with localized scleroderma.

Authors:  Yosef Uziel; Brian M Feldman; Bernice R Krafchik; Ronald M Laxer; Rae Sm Yeung
Journal:  Pediatr Rheumatol Online J       Date:  2007-12-03       Impact factor: 3.054

6.  Periostin in Mature Stage Localized Scleroderma.

Authors:  Min-Woo Kim; Jung Tae Park; Jung Ho Kim; Seong-Joon Koh; Hyun-Sun Yoon; Soyun Cho; Hyun-Sun Park
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

7.  Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab.

Authors:  Danya Traboulsi; Elzbieta A Kaminska; Susan G Barr; Charlene Hunter; P Regine Mydlarski
Journal:  JAAD Case Rep       Date:  2018-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.